Focused On-demand Library for tRNA-dihydrouridine(20) synthase [NAD(P)+]-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9NX74

UPID:

DUS2L_HUMAN

Alternative names:

Dihydrouridine synthase 2; Up-regulated in lung cancer protein 8; tRNA-dihydrouridine synthase 2-like

Alternative UPACC:

Q9NX74; A8K3G3; Q4H4D9

Background:

tRNA-dihydrouridine(20) synthase [NAD(P)+]-like, also known as Dihydrouridine synthase 2 and Up-regulated in lung cancer protein 8, plays a crucial role in the modification of tRNA. It catalyzes the NADPH-dependent synthesis of dihydrouridine, a modified base found in the D-loop of most tRNAs. This enzyme also negatively regulates the activation of EIF2AK2/PKR, highlighting its importance in protein synthesis and cellular stress response mechanisms.

Therapeutic significance:

Understanding the role of tRNA-dihydrouridine(20) synthase [NAD(P)+]-like could open doors to potential therapeutic strategies. Its involvement in tRNA modification and interaction with key cellular stress pathways suggests its potential as a target in diseases where these processes are dysregulated.